Amarin Outlines $100M Cost Saving Plan

Loading...
Loading...
  • Amarin Corporation plc AMRN announced a comprehensive cost and organizational restructuring plan to reduce operating costs by approximately $100 million over the next 12 months.
  • The restructuring will enable Amarin to maintain a positive contribution margin in the U.S. while investing in its European market launches and global expansion for Vascepa/Vazkepa.
  • The majority of the cost savings will result from a significant workforce reduction across the Company's U.S. field force and corporate positions. 
  • Related: Why Amarin Shares Are Plunging After Q1 Earnings.
  • Amarin will reduce its U.S. commercial team by approximately 65% from current levels and approximately 90% of pre-pandemic and pre-generic competition levels, resulting in a core team able to support branded Vascepa revenues in the U.S. 
  • These actions will result in a reduction of the total company employee base by over 40% from current levels.
  • Concurrently, Amarin appointed Tom Reilly as Chief Financial Officer, effective June 20, following the resignation of Michael Kalb.
  • Price Action: AMRN shares are up 3.35% at $1.74 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...